Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
SMMT
Valuation N/A
Summit Therapeutics Inc.
Price$17.17
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +15.0% · above model
SNDL
Valuation N/A
SNDL Inc.
Price$1.22
Model IV—
P/IV—
Limited data — see page
SNDX
Valuation N/A
Syndax Pharmaceuticals Inc
Price$16.90
Model IV—
P/IV—
Market implies +20.3%/yr
SNGX
Valuation N/A
SOLIGENIX, INC.
Price$0.35
Model IV—
P/IV—
Market implies +38.2%/yr
vs model +15.0% · above model
SNSE
Valuation N/A
Sensei Biotherapeutics, Inc.
Price$25.96
Model IV—
P/IV—
Limited data — see page
SNY
Deeply undervalued
Sanofi
Price$40.23
Model IV$312.70
P/IV0.13
Discount 87%
Return to IV: +677.3%
Market implies -21.9%/yr
vs model +7.8% · below model
SNYR
Valuation N/A
Synergy CHC Corp.
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr
SPRB
Valuation N/A
SPRUCE BIOSCIENCES, INC.
Price$45.54
Model IV—
P/IV—
Market implies +21.3%/yr
SPRC
Valuation N/A
SciSparc Ltd.
Price$4.43
Model IV—
P/IV—
Limited data — see page
SPRO
Valuation N/A
Spero Therapeutics, Inc.
Price$1.14
Model IV—
P/IV—
Market implies -2.7%/yr
vs model +42.3% · below model
SPRY
Overvalued
ARS Pharmaceuticals, Inc.
Price$4.56
Model IV$3.75
P/IV2.42
Premium +22%
Return to IV: -17.8%
Market implies +4.6%/yr
vs model +50.0% · below model
SPTX
Valuation N/A
Seaport Therapeutics, Inc.
Price$17.91
Model IV—
P/IV—
Limited data — see page
SRPT
Undervalued
Sarepta Therapeutics, Inc.
Price$18.21
Model IV$22.12
P/IV0.81
Discount 18%
Return to IV: +21.5%
Market implies +1.6%/yr
vs model +32.1% · below model
STOK
Deeply overvalued
Stoke Therapeutics, Inc.
Price$23.95
Model IV$9.85
P/IV3.14
Premium +143%
Return to IV: -58.9%
Market implies +6.9%/yr
vs model +15.0% · below model
STTK
Valuation N/A
Shattuck Labs, Inc.
Price$5.66
Model IV—
P/IV—
Market implies +106.7%/yr
vs model +2.0% · above model
SUPN
Deeply overvalued
SUPERNUS PHARMACEUTICALS, INC.
Price$42.14
Model IV$32.05
P/IV1.35
Premium +31%
Return to IV: -23.9%
Market implies -1.8%/yr
vs model +5.5% · below model
SVA
Fairly valued
SINOVAC BIOTECH LTD
Price$6.47
Model IV$7.57
P/IV0.85
Discount 15%
Return to IV: +17.0%
Market implies -9.9%/yr
vs model +2.0% · below model
SVRA
Valuation N/A
Savara Inc
Price$4.83
Model IV—
P/IV—
Limited data — see page
SXTC
Valuation N/A
China SXT Pharmaceuticals, Inc.
Price$0.34
Model IV—
P/IV—
Market implies -3.1%/yr
vs model +2.0% · below model
SXTP
Deeply undervalued
60 DEGREES PHARMACEUTICALS, INC.
Price$0.97
Model IV$4.54
P/IV0.26
Discount 79%
Return to IV: +366.6%
Market implies -29.3%/yr
vs model +50.0% · below model
SYRE
Valuation N/A
Spyre Therapeutics, Inc.
Price$79.90
Model IV—
P/IV—
Market implies +148.5%/yr
TAK
Deeply undervalued
TAKEDA PHARMACEUTICAL CO LTD
Price$18.52
Model IV$74.81
P/IV0.25
Discount 75%
Return to IV: +303.9%
Market implies -12.8%/yr
vs model +7.0% · below model
TBPH
Deeply undervalued
Theravance Biopharma, Inc.
Price$17.03
Model IV$154.19
P/IV0.10
Discount 89%
Return to IV: +805.4%
Market implies -16.7%/yr
vs model +19.6% · below model
TCRT
Valuation N/A
Alaunos Therapeutics, Inc.
Price$0.78
Model IV—
P/IV—
Market implies +80.4%/yr
vs model +2.0% · above model
TELO
Valuation N/A
Telomir Pharmaceuticals, Inc.
Price$1.15
Model IV—
P/IV—
Limited data — see page
TENX
Valuation N/A
TENAX THERAPEUTICS, INC.
Price$1.86
Model IV—
P/IV—
Limited data — see page
TEVA
Deeply overvalued
TEVA PHARMACEUTICAL INDUSTRIES LTD
Price$39.25
Model IV$20.49
P/IV1.90
Premium +92%
Return to IV: -47.8%
Market implies +14.6%/yr
vs model +7.6% · above model
TGTX
Overvalued
TG THERAPEUTICS, INC.
Price$53.34
Model IV$42.77
P/IV0.89
Premium +25%
Return to IV: -19.8%
Market implies -0.9%/yr
vs model +50.0% · below model
TKNO
Valuation N/A
Alpha Teknova, Inc.
Price$8.44
Model IV—
P/IV—
Market implies +50.6%/yr
vs model +2.4% · above model
TLPH
Valuation N/A
TALPHERA, INC.
Price$1.08
Model IV—
P/IV—
Market implies +117.0%/yr
vs model +2.0% · above model
TLRY
Valuation N/A
Tilray Brands, Inc.
Price$3.59
Model IV—
P/IV—
Market implies +27.4%/yr
vs model +12.5% · above model
TLSA
Valuation N/A
Tiziana Life Sciences Ltd
Price$1.13
Model IV—
P/IV—
Limited data — see page
TLX
Valuation N/A
Telix Pharmaceuticals Ltd
Price$11.01
Model IV—
P/IV—
Limited data — see page
TNGX
Valuation N/A
Tango Therapeutics, Inc.
Price$22.57
Model IV—
P/IV—
Market implies +46.0%/yr
vs model +13.9% · above model
TNXP
Valuation N/A
Tonix Pharmaceuticals Holding Corp.
Price$7.28
Model IV—
P/IV—
Market implies +39.9%/yr
vs model +15.0% · above model
TOVX
Valuation N/A
Theriva Biologics, Inc.
Price$0.23
Model IV—
P/IV—
Limited data — see page
TPST
Valuation N/A
Tempest Therapeutics, Inc.
Price$0.77
Model IV—
P/IV—
Limited data — see page
TRAW
Deeply undervalued
Traws Pharma, Inc.
Price$0.48
Model IV$1.16
P/IV1.26
Discount 58%
Return to IV: +140.5%
Market implies -15.6%/yr
vs model +50.0% · below model
TRAX
Valuation N/A
First Tracks Biotherapeutics, Inc.
Price$32.01
Model IV—
P/IV—
Limited data — see page
TRDA
Valuation N/A
Entrada Therapeutics, Inc.
Price$5.53
Model IV—
P/IV—
Market implies +31.1%/yr
vs model +15.0% · above model
TRIB
Valuation N/A
TRINITY BIOTECH PLC
Price$6.04
Model IV—
P/IV—
Limited data — see page
TRVI
Valuation N/A
Trevi Therapeutics, Inc.
Price$12.83
Model IV—
P/IV—
Limited data — see page
TTRX
Valuation N/A
Turn Therapeutics Inc.
Price$11.39
Model IV—
P/IV—
Limited data — see page
TVRD
Valuation N/A
Tvardi Therapeutics, Inc.
Price$1.08
Model IV—
P/IV—
Market implies -7.1%/yr
vs model +15.0% · below model
TVTX
Deeply overvalued
Travere Therapeutics, Inc.
Price$52.04
Model IV$28.09
P/IV2.13
Premium +85%
Return to IV: -46.0%
Market implies +9.1%/yr
vs model +38.9% · below model
TXMD
Undervalued
TherapeuticsMD, Inc.
Price$2.01
Model IV$2.37
P/IV0.92
Discount 15%
Return to IV: +17.9%
Market implies +1.5%/yr
vs model +10.0% · below model
TYRA
Valuation N/A
Tyra Biosciences, Inc.
Price$19.97
Model IV—
P/IV—
Limited data — see page
UNCY
Valuation N/A
Unicycive Therapeutics, Inc.
Price$4.07
Model IV—
P/IV—
Market implies +59.8%/yr
vs model +15.0% · above model
UPB
Valuation N/A
Upstream Bio, Inc.
Price$4.55
Model IV—
P/IV—
Market implies +62.4%/yr
vs model +9.5% · above model
UPC
Valuation N/A
Universe Pharmaceuticals INC
Price$4.18
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +50.0% · below model
URGN
Valuation N/A
UroGen Pharma Ltd.
Price$36.98
Model IV—
P/IV—
Market implies +35.7%/yr
vs model +23.0% · above model
USNA
Deeply undervalued
USANA HEALTH SCIENCES INC
Price$14.66
Model IV$51.21
P/IV0.36
Discount 71%
Return to IV: +249.3%
Market implies -22.0%/yr
vs model +2.0% · below model
UTHR
Deeply undervalued
UNITED THERAPEUTICS Corp
Price$532.78
Model IV$1,006.54
P/IV0.55
Discount 47%
Return to IV: +88.9%
Market implies +4.2%/yr
vs model +15.1% · below model
VBIO
Valuation N/A
Valion Bio, Inc.
Price$2.21
Model IV—
P/IV—
Market implies +11.6%/yr
VERA
Valuation N/A
Vera Therapeutics, Inc.
Price$29.73
Model IV—
P/IV—
Limited data — see page
VERU
Valuation N/A
VERU INC.
Price$2.42
Model IV—
P/IV—
Market implies +10.5%/yr
vs model +15.0% · below model
VKTX
Valuation N/A
Viking Therapeutics, Inc.
Price$27.73
Model IV—
P/IV—
Limited data — see page
VNDA
Valuation N/A
Vanda Pharmaceuticals Inc.
Price$4.53
Model IV—
P/IV—
Market implies +52.6%/yr
VNRX
Valuation N/A
VOLITIONRX LTD
Price$0.22
Model IV—
P/IV—
Market implies -4.7%/yr
vs model +50.0% · below model
VRAX
Valuation N/A
Virax Biolabs Group Ltd
Price$1.99
Model IV—
P/IV—
Market implies +95.3%/yr
vs model +2.0% · above model